Honokiol synergizes chemotherapy drugs in multidrug resistant breast cancer cells via enhanced apoptosis and additional programmed necrotic death

International Journal of Oncology

Volumn 42, Issue 2, 2013, Pages 721-732

  Tian, Wei ^a   Deng, Yongchuan ^a   Li, Ling ^b   He, Haifei ^a   Sun, Jie ^c   Xu, Dong ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c Department of Physics   (China)

Author keywords

Apoptosis; Breast cancer; Honokiol; Multidrug drug resistance; Programmed necrotic death

Indexed keywords

CHINESE DRUG; CYCLOPHILIN D; CYCLOSPORIN A; CYTOTOXIC AGENT; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; HERBACEOUS AGENT; HONOKOI; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PACLITAXEL; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; HUMAN CELL; IC 50; LEUKEMIA CELL; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; WESTERN BLOTTING;

APOPTOSIS; BIPHENYL COMPOUNDS; BREAST NEOPLASMS; CYCLOPHILINS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ETOPOSIDE; FEMALE; HUMANS; LIGNANS; MCF-7 CELLS;

EID: 84873621298     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1739     Document Type: Article

References (35)

1. Hu X and Xuan Y: Bypassing cancer drug resistance by activating multiple death pathways - a proposal from the study of circumventing cancer drug resistance by induction of necroptosis. Cancer Lett 259: 127-137, 2008.
2. Xu D, Lu Q and Hu X: Down-regulation of P-glycoprotein expression in MDR breast cancer cell MCF-7/ADR by honokiol. Cancer Lett 243: 274-280, 2006.
3. Baguley BC: Multiple drug resistance mechanisms in cancer. Mol Biotechnol 46: 308-316, 2010.
4. Xu D, Tian W and Shen H: Curcumin prevents induced drug resistance: a novel function? Chin J Cancer Res 23: 218-223, 2011.
5. Gillet JP and Gottesman MM: Mechanisms of multidrug resistance in cancer. Methods Mol Biol 596: 47-76, 2010.
6. Gandhi L, Harding MW, Neubauer M, et al: A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer. Cancer 109: 924-932, 2007.
7. Ruff P, Vorobiof DA, Jordaan JP, et al: A randomized, placebo-controlled, double-blind phase 2 study of docetaxel compared to docetaxel plus zosuquidar (LY335979) in women with metastatic or locally recurrent breast cancer who have received one prior chemotherapy regimen. Cancer Chemother Pharmacol 64: 763-768, 2009.
8. Kroemer G, Galluzzi L, Vandenabeele P, et al: Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ 16: 3-11, 2009.
9. Li L, Han W, Gu Y, et al: Honokiol induces a necrotic cell death through the mitochondrial permeability transition pore. Cancer Res 67: 4894-4903, 2007.
10. Xuan Y and Hu X: Naturally-occurring shikonin analogues - a class of necroptotic inducers that circumvent cancer drug resistance. Cancer Lett 274: 233-242, 2009.
11. Guidicelli G, Chaigne-Delalande B, Dilhuydy MS, et al: The necrotic signal induced by mycophenolic acid overcomes apoptosis-resistance in tumor cells. PLoS One 4: e5493, 2009.
12. Ishitsuka K, Hideshima T, Hamasaki M, et al: Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis. Blood 106: 1794-1800, 2005.
13. Wang Y, Yang Z and Zhao X: Honokiol induces paraptosis and apoptosis and exhibits schedule-dependent synergy in combination with imatinib in human leukemia cells. Toxicol Mech Methods 20: 234-241, 2010.
14. Wang T, Chen F, Chen Z, et al: Honokiol induces apoptosis through p53-independent pathway in human colorectal cell line RKO. World J Gastroenterol 10: 2205-2208, 2004.
15. Chen F, Wang T, Wu YF, et al: Honokiol: a potent chemotherapy candidate for human colorectal carcinoma. World J Gastroenterol 10: 3459-3463, 2004.
16. Chou TC and Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55, 1984.
17. Bijnsdorp IV, Giovannetti E and Peters GJ: Analysis of drug interactions. Methods Mol Biol 731: 421-434, 2011.
18. Battle TE, Arbiser J and Frank DA: The natural product honokiol induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia (B-CLL) cells. Blood 106: 690-697, 2005.
19. Steinbach D and Legrand O: ABC transporters and drug resistance in leukemia: was P-gp nothing but the first head of the Hydra? Leukemia 21: 1172-1176, 2007.
20. Golstein P and Kroemer G: Cell death by necrosis: towards a molecular definition. Trends Biochem Sci 32: 37-43, 2007.
21. Vandenabeele P, Galluzzi L, Vanden Berghe T and Kroemer G: Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol 11: 700-714, 2010.
22. Degterev A and Yuan J: Expansion and evolution of cell death programmes. Nat Rev Mol Cell Biol 9: 378-390, 2008.
23. Kinnally KW, Peixoto PM, Ryu SY and Dejean LM: Is mPTP the gatekeeper for necrosis, apoptosis, or both? Biochim Biophys Acta 1813: 616-622, 2011.
24. Oeckinghaus A, Hayden MS and Ghosh S: Crosstalk in NF-kappaB signaling pathways. Nat Immunol 12: 695-708, 2011.
25. Shih VF, Tsui R, Caldwell A and Hoffmann A: A single NFkappaB system for both canonical and non-canonical signaling. Cell Res 21: 86-102, 2011.
26. Hanahan D and Weinberg RA: Hallmarks of cancer: the next generation. Cell 144: 646-674, 2011.
27. Catz SD and Johnson JL: Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer. Oncogene 20: 7342-7351, 2001.
28. Tamatani M, Che YH, Matsuzaki H, et al: Tumor necrosis factor induces Bcl-2 and Bcl-x expression through NFkappaB activation in primary hippocampal neurons. J Biol Chem 274: 8531-8538, 1999.
29. Dong QG, Sclabas GM, Fujioka S, et al: The function of multiple IkappaB : NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis. Oncogene 21: 6510 6519, 2002.
30. Bentires-Alj M, Barbu V, Fillet M, et al: NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene 22: 90-97, 2003.
31. Arora S, Bhardwaj A, Srivastava SK, et al: Honokiol arrests cell cycle, induces apoptosis, and potentiates the cytotoxic effect of gemcitabine in human pancreatic cancer cells. PLoS One 6: e21573, 2011.
32. Ahn KS, Sethi G, Shishodia S, Sung B, Arbiser JL and Aggarwal BB: Honokiol potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through modulation of nuclear factor-kappaB activation pathway. Mol Cancer Res 4: 621-633, 2006.
33. Tse AK, Wan CK, Shen XL, Yang M and Fong WF: Honokiol inhibits TNF-alpha-stimulated NF-kappaB activation and NF-kappaB-regulated gene expression through suppression of IKK activation. Biochem Pharmacol 70: 1443-1457, 2005.
34. Arlt A, Vorndamm J, Breitenbroich M, et al: Inhibition of NF-kappaB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin. Oncogene 20: 859-868, 2001.
35. Nakanishi C and Toi M: Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 5: 297-309, 2005.